Get the Stockscreener App
7.83
23.70%
1.50
Exozymes Inc stock is traded at $7.83, with a volume of 19,994.
It is up +23.70% in the last 24 hours and down -18.01% over the past month.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
See More
Previous Close:
$6.33
Open:
$6.5074
24h Volume:
19,994
Relative Volume:
3.46
Market Cap:
$71.34M
Revenue:
$70,100
Net Income/Loss:
$-9.67M
P/E Ratio:
-6.8022
EPS:
-1.1511
Net Cash Flow:
$-7.09M
1W Performance:
+1.69%
1M Performance:
-18.01%
6M Performance:
-35.82%
1Y Performance:
-36.60%
1-Day Range:
$6.5074
$7.83
1-Week Range:
$6.33
$8.21
52-Week Range:
$6.33
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
7.83 | 71.34M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exozymes Inc Stock (EXOZ) Latest News
eXoZymes Inc (EXOZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
eXoZymes Inc (EXOZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
eXoZymes Inc (EXOZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
eXoZymes closes $5.95M public offering of stock and warrants By Investing.com - Investing.com South Africa
eXoZymes Completes Nasdaq Equity Offering to Fund Pipeline - TipRanks
Exozymes Raises $5.95 Million in Underwritten Equity Offering Led by MDB Capital - TradingView
eXoZymes (NASDAQ: EXOZ) closes $5.95M stock and warrant unit offering - Stock Titan
eXoZymes closes $5.95 million public offering to fund development - scanx.trade
eXoZymes Inc. Announces Closing of $6 Million Public Offering - The Joplin Globe
eXoZymes secures $6M to fund NCT development and product push - Stock Titan
eXoZymes Inc. (EXOZ) Rises 3.3% as Biotech Momentum Builds, Testing Key Resistance at $7.97Positive Gamma - newsline.com
eXoZymes (EXOZ) Prices Public Offering of Units - GuruFocus
eXoZymes Announces Public Equity Offering to Fund Growth - TipRanks
eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal - TradingView
eXoZymes (NASDAQ: EXOZ) sells units in $5.3M underwritten offering - Stock Titan
eXoZymes prices $5.33M offering of units at $18/unit - scanx.trade
exozymes prices $5.3M public offering at $18 per unit - Investing.com
exozymes prices $5.3M public offering at $18 per unit By Investing.com - Investing.com South Africa
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants - ACCESS Newswire
AI enzyme firm eXoZymes prices $5.33M unit deal with resettable warrants - Stock Titan
eXoZymes (NASDAQ: EXOZ) sells 592,270 shares and 296,135 warrants in $18 units - Stock Titan
EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill
eXoZymes (EXOZ) seeks to sell units of common stock and warrants in offering - Stock Titan
eXoZymes (EXOZ) to sell share-and-warrant units; MDB holds 47.8% - Stock Titan
eXoZymes Inc. (EXOZ) Surges 5.5% – Key Levels to Watch After the RallyCash Secured Put - newsline.com
eXoZymes Inc. (EXOZ) Climbs 3.13% as Biotech Stock Tests Key Resistance at $10.74Inside Day Breakout - The Legal Advocate
Number of shareholders of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
EXOZYMES INC. 1Q 2026: Revenue $0 Net income $(2.37M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
eXoZymes (NASDAQ: EXOZ) Q1 2026 loss deepens amid cash burn, planned raise - Stock Titan
TradingKey - TradingKey
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - ACCESS Newswire
eXoZymes Prepares Investor Presentation for Proposed Public Offering - TipRanks
eXoZymes (EXOZ) files investor presentation for proposed securities offering - Stock Titan
Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review
eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat
Damien Alan Perriman Net Worth (2026) - GuruFocus
eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
Exozymes Inc Stock (EXOZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):